Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced new 12-month data for tofersen, an investigational antisense drug for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). The data show that earlier initiation of tofersen compared to delayed initiation (six months later in the open-label extension [OLE] study) slowed declines in clinical function, respiratory function, muscle strength, and quality of life. At the time of the analysis, because the majority of participants survived without permanent ventilation (PV), the median time to death or PV could not be estimated. However, early survival data suggest a lower risk of death or PV with earlier initiation of tofersen. These results are based on new integrated data from the pivotal Phase 3 VALOR study and its OLE study.

New 12-Month Tofersen Data Presented at ENCALS Meeting Show Clinically Meaningful Benefit in People With SOD1-ALS

SAGE Therapeutics

Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.

Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?

Biogen Inc. (BIIB) Down 4.8% Since Last Earnings Report: Can It Rebound?

Biogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor, BIIB122, in adults with early-stage Parkinson's disease. A late-stage study is planned to start later in 2022.

Biogen (BIIB), Denali Begin Mid-Stage Study on Parkinson's Drug

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the Phase 3 SKYLARK Study of zuranolone, an investigational oral drug being evaluated in women with postpartum depression (PPD), met its primary and all key secondary endpoints. Women treated with zuranolone 50 mg (n=98) demonstrated a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, compared to place

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Amgen

Moderna

Pfizer

Could these biotech stocks be worth watching in the stock market today?

What Stocks To Invest In Now? 4 Biotech Stocks To Know

Once heralded as the “golden child,” the Alzheimer's drug Aduhelm has all but been abandoned by its parent Biogen Inc. ( BIIB , Financial), leaving the Cambridge, Massachusetts-based biotech scrambling to fill the void and restore investor confidence.

Biogen All but Throws in the Towel on Once-Promising Alzheimer's Drug

VanEck Vectors Biotech ETF

Gilead Sciences

iShares Nasdaq Biotechnology ETF

SPDR S&P Biotech ETF

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

How Are Biotech ETFs Reacting to These Q1 Earnings Releases?

Novavax

UnitedHealth Group

Veru

Could these health care stocks be the remedy to investors' recent stock market pains?

Best Stocks To Buy Now? 5 Health Care Stocks In Focus

Things haven't been this bad for the company in quite a long time.

Is This Growth Stock Defeated After Collapsing 22% in a Year?

CAMBRIDGE, Mass. & PORTLAND, Maine--(BUSINESS WIRE)-- #DTx--Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis

Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis

The company just announced some big changes.

1 Reason to Buy Biogen Now, and 1 Reason to Wait

Bristol-Myers

Eli Lilly

Merck

Reporters and analysts covering first-quarter earnings from drug companies may have noticed a change in how they account for upfront payments made to finance research and development at companies in which they have acquired equity stakes.

Called to Account: Drug companies are making an accounting change after the SEC cracked down on Biogen

Biogen Inc. (NASDAQ:BIIB ) Q1 2022 Earnings Conference Call May 3, 2022 8:00 AM ET Company Participants Michael Hencke - Head of IR Michel Vounatsos - CEO Priya Singhal - Interim Head, Research and Development Mike McDonnell - CFO Conference Call Participants Matthew Harrison - Morgan Stanley Umer Raffat - Evercore Robyn Karnauskas - Truist Securities Salveen Richter - Goldman Sachs Michael Yee - Jefferies Cory Kasimov - JPMorgan Marc Goodman - SVB Brian Abrahams - RBC Capital Markets Geoff Meacham - Bank of America Merrill Lynch Jay Olson - Oppenheimer Philip Nadeau - Cowen & Company Mohit Bansal - Wells Fargo Operator Good morning. My name is Cecilia and I will be your conference operator today.

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q1 2022 Results - Earnings Call Transcript

Drug-making giant Biogen is in the green today after announcing CEO Michel Vounatsos is stepping down from the role. The post BIIB Stock Treks Higher Amid News That Biogen CEO Michel Vounatsos Is Stepping Down appeared first on InvestorPlace.

BIIB Stock Treks Higher Amid News That Biogen CEO Michel Vounatsos Is Stepping Down

Biogen Inc.'s BIIB, +0.48% decision to let go of its CEO and scrap commercial plans for its controversial Alzheimer's disease drug indicates there isn't much of a future for a drug that was once at the center of the company's strategy.

Beset by challenges with its Alzheimer's disease drug, Biogen pivots

Biogen said on Tuesday its Chief Executive Michel Vounatsos will step down, with the drugmaker adding it would scale down its sales infrastructure for the controversial Alzheimer's drug Aduhelm.

Biogen CEO to leave as Alzheimer's drug struggles

Biogen (BIIB) misses first-quarter estimates for earnings but beats the same for sales. Following no medicare beneficiary access to Aduhelm, Biogen initiates a cost-savings program.

Biogen (BIIB) Q1 Earnings Miss, Aduhelm Setback Leads to Rejig

Biogen Inc (NASDAQ: BIIB) posted Q1 sales of 2.53 billion, beating the consensus of $2.49 billion, down 6% Y/Y. Multiple sclerosis (MS) revenue, including royalties on sales of Ocrevus, of $1.79 billion decreased by 3%.

Read Why Biogen Sares Are Trading Higher After Q1 Earnings

Biogen Inc  (NASDAQ:BIIB) stepped into the earnings confessional today to post first-quarter earnings of $3.62 per share -- lower than the $4.38 per share analysts anticipated -- due to Alzheimer's drug Adulhem inventory write-offs, and dismal sales of multiple sclerosis drug Tecfidera.

Biogen CEO Steps Down After Quarterly Earnings Miss

The company said it will substantially eliminate the sales infrastructure related to Aduhelm, which is intended to provide savings of $1 billion annually when combined with other cost reductions.

Biogen CEO Stepping Down After Struggles With Alzheimer's Drug Aduhelm

Biogen Inc. (BIIB) delivered earnings and revenue surprises of -17.91% and 1.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Q1 Earnings Miss Estimates

Biogen Inc. BIIB, -0.06% said Tuesday that it is conducting a search to replace CEO Michel Vounatsos, who will stay in his role unless a successor is named. The announcement was made in the company's first-quarter earnings, which saw Biogen missing Wall Street's expectations for earnings and revenue.

Biogen CEO Michel Vounatsos to step down

Shares of Biogen Inc. BIIB, -0.06% fell 2.3% in premarket trading on Tuesday after the company missed Wall Street's expectations for revenue and earnings for the first quarter of 2022. Biogen had net income of $303.8 million, or $2.06 per share, in the first quarter of the year, down from $410.20, or $2.69 per share, in the first quarter of last year.

Biogen'a Q1 profit and revenue lag estimates, weighed down by Alzheimer's drug

The biopharmaceutical company says it has begun to eliminate commercial infrastructure for Aduhelm, its Alzheimer's medication.

News for Biogen Stock (BIIB)